Do Statins Really Work?

Cardio Renal Foundation is a 501(c)(3) tax-exempt charity organization. Your donation advances our mission to provide a solution beyond dialysis.

It is one of the most-searched medicine questions there is, and it usually comes from an honest place. You take the pill every day. You feel no different — because a statin is not supposed to feel like anything. A friend tells you his legs ached until he stopped his. A headline calls cholesterol a myth. And the doubt assembles itself: do statins really work, or am I swallowing a daily pill to move a number on a lab sheet? This page walks the evidence the way a careful skeptic deserves — what the trials actually counted, how big the benefit really is, who it is biggest for, and the one place the evidence honestly thins out: advanced kidney disease, which is where this Foundation's readers live. One boundary up front: this page cannot say whether a statin is right for you. It can make sure the conversation you have with your doctor starts from what is actually known.

First, What "Work" Has to Mean

A statin works on paper if it lowers LDL cholesterol — and it does that reliably, by roughly a third to a half depending on the drug and dose. But lowering a number is not the same as helping a person, and the skeptics are right to insist on the difference. So the trials did not stop at the number. They randomized tens of thousands of people to a statin or an identical placebo and counted the events that matter: heart attacks, strokes, bypass and stent procedures, and deaths. When the Cholesterol Treatment Trialists' Collaboration pooled 26 of those trials — about 170,000 participants — the result was consistent: for every 1 mmol/L (about 39 mg/dL) that LDL cholesterol came down, major vascular events fell by about a fifth — roughly 22 percent. The benefit tracked the size of the LDL drop, across drugs, across ages, in people with and without prior heart disease. That is what "works" means in the evidence: fewer of the events, not just a prettier panel.

The Honest Math: a Fifth of What?

Here is the part the advertisements leave out and the skeptics smell. Twenty-two percent is a relative reduction — a fifth off whatever your risk was to begin with. If your underlying risk is high — a prior heart attack, diabetes, kidney disease, years of smoking — a fifth off is a large number of real events avoided. If your risk is low, the same fifth is small in absolute terms: in the trialists' analysis of lower-risk people, each step of LDL lowering prevented about 11 major events per 1,000 people treated for five years. Both of those statements are true, and holding them together is the entire honest answer. A statin is neither a miracle nor a placebo. It is a risk-reduction tool whose payoff is proportional to the risk it is pointed at — which is why the same pill can be near-essential for one person and a reasonable "not yet" for another, and why your own risk, not your neighbor's opinion, is the missing variable in every argument about these drugs. The benefit also accrues with time: the trials show the reduction building year over year, which is why these are prescribed as long-term therapy rather than a course you finish.

The Kidney Chapter, Where the Story Splits

For readers of this page, one chapter matters more than the average, because kidney disease rewrites the risk arithmetic in both directions. People with chronic kidney disease carry some of the highest cardiovascular risk there is — which should make LDL lowering more valuable, not less. The largest test was the SHARP trial: 9,270 people with chronic kidney disease, given a simvastatin-plus-ezetimibe combination or placebo for about five years. LDL came down, and major atherosclerotic events fell by 17 percent — heart attacks, strokes, and procedures, prevented in people whose kidneys were failing. So before dialysis, the evidence says cholesterol lowering works in kidney disease too. But honesty requires the second half. Once people are established on dialysis, the picture blurs: two large trials that started a statin in dialysis patients — the 4D trial (atorvastatin, in people with diabetes on hemodialysis) and AURORA (rosuvastatin, in hemodialysis patients generally) — lowered LDL by over 40 percent and yet did not significantly reduce heart attacks, strokes, or cardiovascular deaths. The dialysis subgroup of SHARP pointed the same way. Kidney specialists' guidelines reflect exactly that split: they do not recommend starting a statin once someone is on dialysis, while people already taking one when they reach dialysis commonly continue it in discussion with their team. Why would a drug that works everywhere else fade there? The leading explanation is that the cardiovascular disease of advanced kidney failure is only partly the cholesterol-plaque disease statins fight — calcified, stiffened vessels and strain on the heart muscle play a larger role, and no pill aimed at LDL reaches those. It is a genuinely open edge of the science, and anyone who tells you the dialysis answer is simple — in either direction — is ahead of the evidence.

What Statins Do Not Do

The skeptic's case is strongest where expectations were inflated, so let this page deflate them. A statin does not dissolve existing plaque or open a narrowed artery; at best it stabilizes plaque and slows its growth. It does not cancel smoking, blood pressure, blood sugar, or weight — in the trials it was added on top of everything else doctors could do, not instead of it. It does not work in a month; the event curves separate over years. And it is not the only way to lower LDL: our companion page on lowering LDL without a statin walks the food pattern, the soluble-fiber and plant-sterol evidence, and the non-statin medicines, with the same honesty about sizes — the diet route is real, and for most people it moves the number less than the pill does. Knowing what a tool cannot do is part of knowing whether it works.

The Myth in the Middle: "It Only Moves a Number"

The most durable myth about statins is that the benefit is a bookkeeping trick — that doctors treat a lab value while patients gain nothing. The trial design itself busts it: the 170,000 people in those pooled trials were not followed to see whether their cholesterol looked better. They were followed to count heart attacks and strokes, and fewer happened in the statin groups. You can reasonably debate how large the benefit is for a person at your level of risk — that debate is legitimate and this page has tried to arm it honestly. But "nothing happens except a number changes" is not a position the evidence leaves standing.

What to Ask Your Doctor

Four questions turn this page into a decision. What is my personal risk of a heart attack or stroke over the next ten years — the number the benefit is a fraction of? Given my kidney function, which chapter of the evidence am I in — the clear one, or the dialysis one? If I take it, how much LDL reduction should we expect, and when do we check? And if side effects have stopped me before, what is the plan — a different statin, a lower dose, a non-statin partner — rather than simply giving up the benefit? If you want the number itself explained first, our page on what high LDL means starts there.

Why This Research Matters

Notice where the evidence runs out: at the dialysis door, where the heart disease of kidney failure stops behaving like the disease the medicines were built for. That gap is this Foundation's reason to exist. The Cardio Renal Foundation supports research toward a solution beyond dialysis — research aimed at the shared territory where heart and kidney disease drive each other, the calcified vessels and strained hearts and failing filters that today's best pills only partly reach. That is a direction, not a promise — but it is aimed squarely at the burden this question represents.

So — do statins really work? Yes, in the only sense that counts: in trial after trial they prevented real heart attacks and real strokes, by about a fifth for each solid step of LDL lowering, with the payoff sized by the risk of the person taking them. The benefit is clearest in people at higher risk, holds in kidney disease before dialysis, and honestly fades in the trials once dialysis begins. That is the whole answer — neither the sales pitch nor the myth, but the evidence, with its edges showing.

At the Cardio Renal Foundation (Cardio Renal Foundation Inc, EIN 33-4359765), we publish education for exactly this reader — pill bottle in hand, asking whether it earns its place. Support from readers like you helps us keep publishing it.

This article is informational only and is not meant to replace the advice of your qualified healthcare provider. It does not recommend starting, stopping, or changing any medicine: whether a statin belongs in your life depends on your own risk, kidneys, and history, and belongs in a conversation with your clinician. Chest pain, sudden weakness or numbness, trouble speaking, or sudden vision loss can signal an emergency: call 911 immediately. Research supported by this Foundation is investigational only. As with any issues related to your health, check with your doctor.